BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12167561)

  • 1. Catalytic specificity of CYP2D isoforms in rat and human.
    Hiroi T; Chow T; Imaoka S; Funae Y
    Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
    Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
    Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver.
    Chow T; Imaoka S; Hiroi T; Funae Y
    Drug Metab Dispos; 1999 Feb; 27(2):188-92. PubMed ID: 9929501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of CYP2D3 in polymorphism of diazepam p-hydroxylation in rats.
    Sakai N; Saito K; Kim HS; Kazusaka A; Ishizuka M; Funae Y; Fujita S
    Drug Metab Dispos; 2005 Nov; 33(11):1657-60. PubMed ID: 16081673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of desipramine on bufuralol 1''-hydroxylation by rat and human CYP2D enzymes.
    Isobe T; Hichiya H; Hanioka N; Yamamoto S; Shinoda S; Funae Y; Satoh T; Yamano S; Narimatsu S
    Biol Pharm Bull; 2005 Apr; 28(4):634-40. PubMed ID: 15802801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study.
    Bromek E; Haduch A; Daniel WA
    Eur J Pharmacol; 2010 Jan; 626(2-3):171-8. PubMed ID: 19818757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain.
    Kishimoto W; Hiroi T; Shiraishi M; Osada M; Imaoka S; Kominami S; Igarashi T; Funae Y
    Endocrinology; 2004 Feb; 145(2):699-705. PubMed ID: 14563706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression.
    Schulz-Utermoehl T; Bennett AJ; Ellis SW; Tucker GT; Boobis AR; Edwards RJ
    Pharmacogenetics; 1999 Jun; 9(3):357-66. PubMed ID: 10471068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
    Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain.
    Niwa T; Okada K; Hiroi T; Imaoka S; Narimatsu S; Funae Y
    Biol Pharm Bull; 2008 Mar; 31(3):348-51. PubMed ID: 18310890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
    Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
    Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
    Prueksaritanont T; Dwyer LM; Cribb AE
    Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
    Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
    Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol.
    Narimatsu S; Kazamori D; Masuda K; Katsu T; Funae Y; Naito S; Nakura H; Yamano S; Hanioka N
    Biochem Pharmacol; 2009 Mar; 77(5):920-31. PubMed ID: 19059219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
    Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
    J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform-selective metabolism of mianserin by cytochrome P-450 2D.
    Chow T; Hiroi T; Imaoka S; Chiba K; Funae Y
    Drug Metab Dispos; 1999 Oct; 27(10):1200-4. PubMed ID: 10497148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.
    Nakamura A; Yamamoto Y; Tasaki T; Sugimoto C; Masuda M; Kazusaka A; Fujita S
    Drug Metab Dispos; 1995 Nov; 23(11):1268-73. PubMed ID: 8591729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
    Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
    Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.